• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 3. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 4. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 5. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474

Professional Introduction to 2,5-dibromo-4-hydroxybenzoic acid (CAS No. 101421-19-6)

2,5-dibromo-4-hydroxybenzoic acid, identified by the Chemical Abstracts Service Number (CAS No.) 101421-19-6, is a halogenated aromatic carboxylic acid that has garnered significant attention in the field of pharmaceutical chemistry and materials science due to its versatile structural properties and potential biological activities. This compound, featuring both hydroxyl and bromine substituents on a benzoic acid backbone, presents a unique chemical profile that makes it a valuable intermediate in synthetic chemistry and a candidate for further exploration in drug discovery.

The structural motif of 2,5-dibromo-4-hydroxybenzoic acid consists of a phenyl ring substituted with hydroxyl groups at the 4-position and bromine atoms at the 2- and 5-positions. This specific arrangement imparts distinct electronic and steric properties to the molecule, influencing its reactivity and interaction with biological targets. The presence of both electron-withdrawing (bromine) and electron-donating (hydroxyl) groups creates a balance that can modulate the compound's solubility, stability, and binding affinity in various applications.

In recent years, the pharmaceutical industry has shown increasing interest in halogenated aromatic compounds due to their enhanced bioavailability and metabolic stability. 2,5-dibromo-4-hydroxybenzoic acid is no exception, as studies have begun to uncover its potential in developing novel therapeutic agents. Its brominated structure suggests possible applications in the synthesis of kinase inhibitors, anticancer drugs, and antimicrobial agents, where halogen atoms often play a crucial role in improving pharmacokinetic profiles.

One of the most compelling aspects of 2,5-dibromo-4-hydroxybenzoic acid is its utility as a building block in medicinal chemistry. Researchers have leveraged its scaffold to design derivatives with improved pharmacological properties. For instance, modifications at the 3-position or introduction of additional functional groups can yield compounds with enhanced receptor binding or altered metabolic pathways. Such structural diversification is essential for optimizing drug candidates through high-throughput screening and rational drug design.

The compound's reactivity also makes it a valuable tool in synthetic organic chemistry. The hydroxyl group at the 4-position allows for esterification, etherification, or amidation reactions, while the bromine atoms at the 2- and 5-positions can undergo cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These transformations enable chemists to construct more complex molecules with tailored properties for industrial or research applications.

Recent advancements in computational chemistry have further highlighted the significance of 2,5-dibromo-4-hydroxybenzoic acid. Molecular modeling studies have predicted its interactions with various biological targets, providing insights into potential therapeutic effects. For example, simulations suggest that this compound may interfere with DNA replication in cancer cells by inhibiting key enzymes like topoisomerases or kinases. Such findings are particularly relevant given the ongoing efforts to develop targeted therapies for resistant malignancies.

Moreover, 2,5-dibromo-4-hydroxybenzoic acid has found applications beyond pharmaceuticals. In materials science, its ability to form coordination complexes with metal ions has been explored for developing luminescent probes or catalysts. The bromine atoms facilitate coordination with transition metals such as copper or palladium, while the hydroxyl group can participate in hydrogen bonding interactions. These properties make it a promising candidate for creating functional materials with applications in sensors or optoelectronics.

The synthesis of 2,5-dibromo-4-hydroxybenzoic acid typically involves bromination followed by hydroxylation of an appropriate precursor. Advances in green chemistry have led to more sustainable methods for these transformations, including catalytic processes that minimize waste generation. Such innovations align with global efforts to promote environmentally friendly chemical manufacturing practices.

As research continues to uncover new applications for halogenated aromatic compounds like 2,5-dibromo-4-hydroxybenzoic acid, collaborations between academia and industry are becoming increasingly vital. These partnerships accelerate the translation of laboratory discoveries into practical solutions by combining expertise in synthetic chemistry, pharmacology, and materials science. The compound's multifaceted potential underscores its importance as a chemical entity worthy of further investigation.

In conclusion,2,5-dibromo-4-hydroxybenzoic acid (CAS No. 101421-19-6) represents a fascinating intersection of structure and function that holds promise across multiple scientific disciplines. Its unique chemical features make it an indispensable tool for researchers seeking novel therapeutics or advanced materials. As our understanding of its properties evolves through ongoing studies, this compound is poised to play an increasingly significant role in addressing challenges in medicine and technology.

• 14348-40-4(TBHBA)
• 14348-41-5(3-Bromo-4-hydroxybenzoic acid)
• 65849-33-4(Phenol, 2-bromo-4-methyl-, benzoate)
• 207728-74-3(Benzoic acid,2,4,6-tribromo-3-hydroxy-, hydrate (1:1))
• 61040-90-2(Benzoic acid, 2,6-dibromo-3,5-dihydroxy-4-methyl-)
• 3337-62-0(3,5-Dibromo-4-hydroxybenzoic acid)
• 35754-69-9(Benzoic acid, 2,3,4,5-tetrabromo-6-hydroxy-)
• 58380-11-3(2-Bromo-5-hydroxybenzoic acid)
• 61203-47-2(Benzoic acid, 2-bromo-4,5-dihydroxy-)
• 74317-85-4(2-Bromo-4-methoxybenzoic acid)